Mitoxantrone in progressive multiple sclerosis: a placebo-controlled, double-blind, randomised, multicentre trial (Q44264108)

1 December 2017

Mitoxantrone in progressive multiple sclerosis: a placebo-controlled, double-blind, randomised, multicentre trial (English)

1 reference

multicenter clinical trial

1 December 2017

0 references

1 reference

1 reference

1

Hans-Peter Hartung

1 reference

1 December 2017

4

Hubert Kwiecinski

1 reference

1 December 2017

Richard Gonsette

2

1 reference

1 December 2017

Nikolaus König

3

1 reference

1 December 2017

Andreas Guseo

5

1 reference

1 December 2017

Sean P Morrissey

6

1 reference

1 December 2017

Hilmar Krapf

7

1 reference

1 December 2017

Thomas Zwingers

8

1 reference

1 December 2017

Mitoxantrone in Multiple Sclerosis Study Group (MIMS)

9

1 reference

1 December 2017

language of work or name

English

0 references

publication date

1 December 2002

1 reference

1 December 2017

1 reference

1 December 2017

360

1 reference

1 December 2017

2018-2025

1 reference

1 December 2017

9350

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2802%2912023-X

1 December 2017

1 reference

7 January 2021

Defining the clinical course of multiple sclerosis: Results of an international survey

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2802%2912023-X

7 January 2021

Randomized controlled trial of interferon- beta-1a in secondary progressive MS: Clinical results

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2802%2912023-X

7 January 2021

Benefit of interferon beta-1a on MSFC progression in secondary progressive MS.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2802%2912023-X

7 January 2021

Rating neurologic impairment in multiple sclerosis: An expanded disability status scale (EDSS)

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2802%2912023-X

7 January 2021

Mitoxantrone: a new anticancer drug with significant clinical activity

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2802%2912023-X

7 January 2021

Suppression of demyelination by mitoxantrone

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2802%2912023-X

7 January 2021

Suppression of acute and relapsing experimental allergic encephalomyelitis with mitoxantrone

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2802%2912023-X

7 January 2021

Suppression of experimental allergic encephalomyelitis by mitoxantrone.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2802%2912023-X

7 January 2021

An open-trial evaluation of mitoxantrone in the treatment of progressive MS.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2802%2912023-X

7 January 2021

Intensive immunosuppression in progressive multiple sclerosis. A randomized, three-arm study of high-dose intravenous cyclophosphamide, plasma exchange, and ACTH.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2802%2912023-X

7 January 2021

Magnetic resonance imaging in monitoring the treatment of multiple sclerosis: concerted action guidelines

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2802%2912023-X

7 January 2021

Therapeutic effect of mitoxantrone combined with methylprednisolone in multiple sclerosis: a randomised multicentre study of active disease using MRI and clinical criteria

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2802%2912023-X

7 January 2021

Two-Sample Asymptotically Distribution-Free Tests for Incomplete Multivariate Observations

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2802%2912023-X

7 January 2021

A SELF-RATING DEPRESSION SCALE

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2802%2912023-X

7 January 2021

Randomized placebo-controlled trial of mitoxantrone in relapsing-remitting multiple sclerosis: 24-month clinical and MRI outcome

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2802%2912023-X

7 January 2021

Noninvasive Assessment of Mitoxantrone Cardiotoxicity in Relapsing Remitting Multiple Sclerosis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2802%2912023-X

7 January 2021

Intramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis. The Multiple Sclerosis Collaborative Research Group (MSCRG)

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2802%2912023-X

7 January 2021

Control of immune-mediated disease of the central nervous system requires the use of a neuroactive agent: elucidation by the action of mitoxantrone

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2802%2912023-X

7 January 2021

10.1016/S0140-6736(02)12023-X

Identifiers

DOI

1 reference

1 December 2017

1 reference